PARP inhibitors for the treatment of ovarian cancer
Podcast 2021034
Questions:
- Which is the mechanism of action of PARP inhibitors and why this is relevant in ovarian cancer?
- How can we measure the homologous recombination deficiency?
- Which is the current evidence for the use of maintenance PARP inhibitors in recurrent epithelial ovarian cancer?
- Can you tell us which are the results of phase 3 trials that have investigated PARP inhibitors in front line treatment of epithelial ovarian cancer?
- Which are the main toxicities of PARP inhibitors?
Expert
/attachment.e-eso.net/48/2021072809110396.jpg)
Medical oncologist
Oncology Institute of Southern Switzerland (IOSI)
Bellinzona, Switzerland
Oncology Institute of Southern Switzerland (IOSI)
Bellinzona, Switzerland
02
Dec 2021
